A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback